Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase III of Obinutuzumab and Venetoclax in Untreated CLL without 17p deletion or Tp53 mutation

A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION

Disease Types: Leukemia

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION

For more information:

https://clinicaltrials.gov/ct2/show/NCT04285567?term=A+PROSPECTIVE%2C+OPEN-LABEL%2C+MULTICENTER+RANDOMIZED+PHASE+III+TRIAL+TO+COMPARE+THE+EFFICACY+AND+SAFETY+OF+A+COMBINED+REGIMEN+OF+OBINUTUZUMAB+AND+VENETOCLAX+VERSUS+FLUDARABINE%2C+CYCLOPHOSPHAMIDE+AND+RITUXIMAB+%28FCR%29%2F+BENDAMUSTINE+AND+RITUXIMAB+%28BR%29+IN+FIT&draw=2&rank=1